Cayman and GenScript have announced a collaboration to create a complete package of neoantigen discovery services. Through combined efforts, MHC-associated peptides are identified and verified as immunogenic to guide peptide synthesis for vaccine development.
“Cayman provides a complete workflow enabling the identification of peptide sequences as putative neoantigens. We are excited to add GenScript’s technical means and experience to synthesize peptides for our clients’ downstream applications and potential vaccine development,” said Dr. Michael Pisano, VP of Business Development and Contract Services at Cayman.
Their service has a wide range of applications for neoantigen discovery projects, ranging from the functional screening of candidates for T cell receptor therapy to clinical-stage peptide vaccine testing.
“GenScript is excited to start this partnership with Cayman to provide a full immunopeptidome discovery and production service. By combining Cayman’s industry-leading expertise in immunopeptidome profiling with GenScript’s reliable service for difficult neoantigen peptide synthesis, we can offer a full-spectrum platform for the personalized immuno-oncology community,” said Dr. Samantha Zaroff, Product Manager of Neoantigen Peptides at GenScript.